Citations

Clear

2 citation(s) found for "Shaikh, Zainab H".

Exploring the landscape of viral hepatitis: A comprehensive retrospective analysis of mortality trends and disparities in the United States (1999–2020)
Idrees, Usama , Nasir, Safa , Marsool, Mohammad Dheyaa, Saeed, Humza, Fatima, Zainab , Mujeeb, Aafeen , Saeed, Khansha, Shahid, Iqra , Sehar, Ayesha, Imtiaz, Abdullah, Alam, Md Shah , Ahmad, Muhammad Husnain , Marsool, Mohammad Dheyaa Marsool, Saeed, Humza , Saeed, Khansha, Najafi, Syed Muhammad Ali, Ahmed, Ali

Mayo Clinic

Medicine | November 14, 2025 | Volume: 104 | Issue: 46 | Pages: e45793

10.1097/md.0000000000045793 | PMID 41239636 Get It

Viral hepatitis (VH) remains a leading cause of preventable mortality in the United States (US). Despite advancements in antiviral therapies, disparities in VH-related mortality persist across demographic, racial, and geographic groups. This study analyzes trends in VH-related mortality among US adults between 1999 and 2020 to identify high-risk subgroups and inform public health interventions. This retrospective cohort study analyzed VH-related deaths among US adults (≥25 years). Data were obtained from the CDC WONDER database, with cases identified using the International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) codes B15–B19. Age-adjusted mortality rates (AAMRs) were calculated per 1,00,000 individuals and stratified by age, gender, race and geographical location. Temporal trends in mortality were analyzed by estimating annual percentage changes (APCs) in the AAMRs using the joinpoint regression model. A total of 3,59,035 VH-related deaths were recorded among US adults during 1999 to 2020 with a cumulative overall AAMR of 7.36 (95% CI: 7.33–7.38). Overall, the AAMRs increased significantly from 1999 to 2013 (APC: +3.21; P < .01), followed by a significant decline until 2020 (APC: −5.61; P < .01). Men exhibited higher AAMRs than women, with middle-aged adults (45–64 years) most affected compared to young (25–44 years) and older adults (65 to 85+ years). Non-Hispanic (NH) American Indians/Alaska experienced the highest AAMRs followed by NH Blacks/African Americans, Hispanics, NH Asians/Pacific Islanders and NH Whites populations. Geographically, mortality rates were higher in urban areas than in rural areas, in the Western region relative to other regions and in the District of Columbia compared to other states. Significant disparities in VH-related mortality persist across demographic and geographic subgroups, with particularly higher rates among men, NH American Indian/Alaska Native population, middle-aged adults, and residents of urban and Western US regions. Targeted public health strategies are essential to address these inequities and improve outcomes.
IMMU-25. B-CELL BASED THERAPY (BVAX) PRODUCES ANTIBODIES TO SUPPRESS GLIOBLASTOMA TUMOR MIGRATION AND INVASION
Katz, Joshua , Cervantes, Gustavo Ignacio Vázquez , Olson, Ian , Hou, David , Dapash, Mark , Wan, Hanxiao, Rashidi, Aida , Arjmandi, Tarlan, Shaikh, Zainab H, Jones, Grace, Zhang, Peng , Heimberger, Amy B. , Riviere-Cazaux, Cécile , Miska, Jason , Fischietti, Mariafausta, Castro, Brandyn , Wang, Si , Arrieta, Victor Andrés , Najem, Hinda , Jones, Grace, Platanias, Leonidas C. , McCortney, Kathleen , Horbinski, Craig , Stupp, Roger , Ahmed, Atique U. , Sonabend, Adam M , Heimberger, Amy B. , Lesniak, Maciej S. , Burns, Terry C. , Fischietti, Mariafausta , Lee-Chang, Catalina

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii157-viii158

10.1093/neuonc/noae165.0618 Get It

Abstract Glioblastoma (GBM) presents as a highly aggressive and malignant brain tumor with limited treatment options. Despite the availability of existing therapies, the invasive characteristics of GBM frequently result in tumor recurrence and poor prognosis. We previously developed a B-cell-based therapy (BVax) that has shown promising results in its ability to induce therapeutic responses in preclinical models of GBM. Our research revealed potency of BVax can be attributed to its robust antigen-presenting capability, cognate antigen specificity with T cells, and ability to generate tumor-reactive antibodies. The present study aims to characterize the unique antigenic reactivity of BVax-derived antibodies by evaluating their immunological effects and therapeutic potential in both murine models and GBM patient-specific samples. Leveraging CD45.1 and CD45.2 congenic mouse models, we first revealed that BVax preferentially migrated to glioma-bearing brains upon intravenous injection, resulting in a CD38+CD20-CD19+ plasmablast phenotype. To further characterize the reactivity of BVax-derived immunoglobulins (Ig), we utilized proteomic analysis and identified preferential targets of Gelsolin, Fibronectin, Versican, Fibrinogen, and collagen type IV alpha, commonly associated with cell motility and the extracellular matrix. Microdialysis data confirmed the increased presence of many of these BVax-derived Igs-recognized antigens in tumor regions compared to normal brain regions in GBM patients. Utilizing purified BVax-derived antibodies from patient specimen, in vitro cell motility assays demonstrated a significant prevention of the invasion and migration of cell lines from patient derived xenograft (PDX). In this study, we concluded that BVax elicits antitumor activity through targeted migration to tumor-bearing regions, differentiation into plasmablasts, and robust secretion of specific Igs that retain the ability to inhibit functionalities associated with cell invasion and migration. Here, we present the first in-depth study that characterizes GBM patients’ antibody reactivity, specifically a subset of inflammatory B cells (BVax) with therapeutic effects that offer an indication for a new direction of immunotherapies.